David Allman

TL;DR: Oral capecitabine achieved an at least equivalent efficacy compared with IV 5-FU/LV as first-line treatment for metastatic colorectal cancer and demonstrated clinically meaningful safety advantages and the convenience of an oral agent.

TL;DR: The intermittent single-agent capecitabine schedule is proposed for phase III evaluation, based on considerations of toxicity, dose-intensity, response rate, and TTP.

TL;DR: Capecitabine is a tolerable oral outpatient therapy that shows promising clinical activity in a variety of cancers and is recommended by the recommended phase II dose.

TL;DR: It is recommended that capecitabine be administered with food as this procedure was used in the clinical trials, and a profound influence on Cmax of cape citabine and most of its metabolites was found.

TL;DR: Capecitabine (Xeloda) is a novel rationally designed fluoropyrimidine carbamate that passes through the intestinal mucosal membrane intact and is subsequently activated by a cascade of three enzymes resulting in preferential release of 5-fluorouracil (5-FU) at the tumor site.